BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rodríguez-Perálvarez M, Germani G, Papastergiou V, Tsochatzis E, Thalassinos E, Luong TV, Rolando N, Dhillon AP, Patch D, O’Beirne J. Early tacrolimus exposure after liver transplantation: relationship with moderate/severe acute rejection and long-term outcome. J Hepatol. 2013;58:262-270. [PMID: 23023010 DOI: 10.1016/j.jhep.2012.09.019] [Cited by in Crossref: 64] [Cited by in F6Publishing: 56] [Article Influence: 6.4] [Reference Citation Analysis]
Number Citing Articles
1 Sarkar M, Watt KD, Terrault N, Berenguer M. Outcomes in liver transplantation: Does sex matter? J Hepatol. 2015;62:946-955. [PMID: 25433162 DOI: 10.1016/j.jhep.2014.11.023] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 5.1] [Reference Citation Analysis]
2 Khorsandi SE, Heaton N. Optimization of immunosuppressive medication upon liver transplantation against HCC recurrence. Transl Gastroenterol Hepatol 2016;1:25. [PMID: 28138592 DOI: 10.21037/tgh.2016.03.18] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
3 Jadlowiec CC, Morgan PE, Nehra AK, Hathcock MA, Kremers WK, Heimbach JK, Wiesner RH, Taner T. Not All Cellular Rejections Are the Same: Differences in Early and Late Hepatic Allograft Rejection. Liver Transpl. 2019;25:425-435. [PMID: 30615251 DOI: 10.1002/lt.25411] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
4 Jia JJ, Lin BY, He JJ, Geng L, Kadel D, Wang L, Yu DD, Shen T, Yang Z, Ye YF, Zhou L, Zheng SS. ''Minimizing tacrolimus'' strategy and long-term survival after liver transplantation. World J Gastroenterol 2014; 20(32): 11363-11369 [PMID: 25170223 DOI: 10.3748/wjg.v20.i32.11363] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
5 Pardo F, Pons JA, Briceño J. V Reunión de Consenso de la Sociedad Española de Trasplante Hepático sobre receptores de riesgo elevado, escenarios actuales de inmunosupresión y manejo del hepatocarcinoma en espera de trasplante. Gastroenterología y Hepatología 2015;38:600-18. [DOI: 10.1016/j.gastrohep.2015.06.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
6 Lerut JP, Pinheiro RS, Lai Q, Stouffs V, Orlando G, Juri JM, Ciccarelli O, Sempoux C, Roggen FM, De Reyck C. Is minimal, [almost] steroid-free immunosuppression a safe approach in adult liver transplantation? Long-term outcome of a prospective, double blind, placebo-controlled, randomized, investigator-driven study. Ann Surg. 2014;260:886-91; discussion 891-2. [PMID: 25379858 DOI: 10.1097/sla.0000000000000969] [Cited by in Crossref: 35] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
7 Rodríguez-Perálvarez M, De la Mata M, Tsochatzis E. Tacrolimus Trough Concentrations After Liver Transplantation: Back to the Future. Transplantation 2020;104:e114. [PMID: 31880755 DOI: 10.1097/TP.0000000000003086] [Reference Citation Analysis]
8 Burra P, Shalaby S, Zanetto A. Long-term care of transplant recipients: De novo neoplasms after liver transplantation. Curr Opin Organ Transplant. 2018;23:187-195. [PMID: 29324517 DOI: 10.1097/mot.0000000000000499] [Cited by in Crossref: 13] [Cited by in F6Publishing: 2] [Article Influence: 4.3] [Reference Citation Analysis]
9 Decrocq-Rudler MA, Chan Kwong AHP, Meunier L, Fraisse J, Ursic-Bedoya J, Khier S. Can We Predict Individual Concentrations of Tacrolimus After Liver Transplantation? Application and Tweaking of a Published Population Pharmacokinetic Model in Clinical Practice. Ther Drug Monit 2021;43:490-8. [PMID: 33560099 DOI: 10.1097/FTD.0000000000000867] [Reference Citation Analysis]
10 Ascha MS, Ascha ML, Hanouneh IA. Management of immunosuppressant agents following liver transplantation: Less is more. World J Hepatol 2016; 8(3): 148-161 [PMID: 26839639 DOI: 10.4254/wjh.v8.i3.148] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
11 Klintmalm GB, Saab S, Hong JC, Nashan B. The role of mammalian target of rapamycin inhibitors in the management of post-transplant malignancy. Clin Transplant. 2014;28:635-648. [PMID: 24628264 DOI: 10.1111/ctr.12357] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
12 Charlton M, Levitsky J, Aqel B, OʼGrady J, Hemibach J, Rinella M, Fung J, Ghabril M, Thomason R, Burra P, Little EC, Berenguer M, Shaked A, Trotter J, Roberts J, Rodriguez-Davalos M, Rela M, Pomfret E, Heyrend C, Gallegos-Orozco J, Saliba F. International Liver Transplantation Society Consensus Statement on Immunosuppression in Liver Transplant Recipients. Transplantation 2018;102:727-43. [PMID: 29485508 DOI: 10.1097/TP.0000000000002147] [Cited by in Crossref: 61] [Cited by in F6Publishing: 22] [Article Influence: 20.3] [Reference Citation Analysis]
13 Zhu JQ, Wang J, Li XL, Xu WL, Lv SC, Zhao X, Lang R, He Q. A combination of the percentages of IFN-γ+CD4+T cells and granzyme B+CD19+B cells is associated with acute hepatic rejection: a case control study. J Transl Med 2021;19:187. [PMID: 33933100 DOI: 10.1186/s12967-021-02855-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Rodríguez-perálvarez M, Tsochatzis E, Naveas MC, Pieri G, García-caparrós C, O’beirne J, Poyato-gonzález A, Ferrín-sánchez G, Montero-álvarez JL, Patch D, Thorburn D, Briceño J, De la Mata M, Burroughs AK. Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma. Journal of Hepatology 2013;59:1193-9. [DOI: 10.1016/j.jhep.2013.07.012] [Cited by in Crossref: 96] [Cited by in F6Publishing: 98] [Article Influence: 10.7] [Reference Citation Analysis]
15 Di Maira T, Sapisochin G, Lilly L, Fonés V, Berenguer M. Posttransplant Calcineurin Inhibitors Levels and Intrapatient Variability Are Not Associated With Long-term Outcomes Following Liver Transplantation. Transplantation 2020;104:1201-9. [PMID: 31609904 DOI: 10.1097/TP.0000000000002987] [Reference Citation Analysis]
16 Schütz E, Fischer A, Beck J, Harden M, Koch M, Wuensch T, Stockmann M, Nashan B, Kollmar O, Matthaei J, Kanzow P, Walson PD, Brockmöller J, Oellerich M. Graft-derived cell-free DNA, a noninvasive early rejection and graft damage marker in liver transplantation: A prospective, observational, multicenter cohort study. PLoS Med 2017;14:e1002286. [PMID: 28441386 DOI: 10.1371/journal.pmed.1002286] [Cited by in Crossref: 82] [Cited by in F6Publishing: 77] [Article Influence: 16.4] [Reference Citation Analysis]
17 Sanchez-Torrijos Y, Ampuero J, Romero-Gómez M. Cardiovascular assessment in liver transplant for non-alcoholic steatohepatitis patients: What we do, what we should do. World J Hepatol 2017; 9(15): 697-703 [PMID: 28596817 DOI: 10.4254/wjh.v9.i15.697] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
18 Kanzow P, Kollmar O, Schütz E, Oellerich M, Schmitz J, Beck J, Walson PD, Slotta JE. Graft-derived cell-free DNA as an early organ integrity biomarker after transplantation of a marginal HELLP syndrome donor liver. Transplantation 2014;98:e43-5. [PMID: 25171533 DOI: 10.1097/TP.0000000000000303] [Cited by in Crossref: 27] [Cited by in F6Publishing: 11] [Article Influence: 3.4] [Reference Citation Analysis]
19 Ciria R, Gómez-Luque I, Cortés M, Khorsandi SE, Ayllón MD, Rodríguez-Perálvarez M, López-Cillero P, De La Mata M, O'Grady J, Heaton N, Briceño J. Interaction between tacrolimus, MELD score and acute kidney injury after liver transplantation. Analysis on a large contemporary bicenter meld-era series. Clin Transplant 2020;34:e13890. [PMID: 32356404 DOI: 10.1111/ctr.13890] [Reference Citation Analysis]
20 Fatourou EM, Tsochatzis EA. Management of metabolic syndrome and cardiovascular risk after liver transplantation. Lancet Gastroenterol Hepatol. 2019;4:731-741. [PMID: 31387736 DOI: 10.1016/s2468-1253(19)30181-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
21 Frisch N, Eichler A, Plank AC, Golub Y, Moll GH, Kratz O. Exploring Reference Values for Hair Cortisol: Hair Weight Versus Hair Protein. Ther Drug Monit 2020;42:902-8. [PMID: 33186335 DOI: 10.1097/FTD.0000000000000779] [Reference Citation Analysis]
22 Iesari S, Ackenine K, Foguenne M, De Reyck C, Komuta M, Bonaccorsi Riani E, Ciccarelli O, Coubeau L, Lai Q, Gianello P, Lerut J. Tacrolimus and Single Intraoperative High-dose of Anti-T-lymphocyte Globulins Versus Tacrolimus Monotherapy in Adult Liver Transplantation: One-year Results of an Investigator-driven Randomized Controlled Trial. Annals of Surgery 2018;268:776-83. [DOI: 10.1097/sla.0000000000002943] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
23 Londoño MC, Rimola A, O'Grady J, Sanchez-Fueyo A. Immunosuppression minimization vs. complete drug withdrawal in liver transplantation. J Hepatol 2013;59:872-9. [PMID: 23578883 DOI: 10.1016/j.jhep.2013.04.003] [Cited by in Crossref: 65] [Cited by in F6Publishing: 51] [Article Influence: 7.2] [Reference Citation Analysis]
24 Oellerich M, Beck J, Kanzow P, Schmitz J, Kollmar O, Walson PD, Schütz E. Graft-derived cell-free DNA as a marker of graft integrity after transplantation. Personalized Immunosuppression in Transplantation. Elsevier; 2016. pp. 153-76. [DOI: 10.1016/b978-0-12-800885-0.00007-2] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
25 Toniutto P, Germani G, Ferrarese A, Bitetto D, Zanetto A, Fornasiere E, Fumolo E, Shalaby S, Burra P. An Essential Guide for Managing Post-Liver Transplant Patients: What Primary Care Physicians Should Know. Am J Med 2021:S0002-9343(21)00561-1. [PMID: 34508700 DOI: 10.1016/j.amjmed.2021.08.005] [Reference Citation Analysis]
26 De Simone P, Carrai P, Coletti L, Ghinolfi D, Petruccelli S, Filipponi F. Modification of immunosuppressive therapy as risk factor for complications after liver transplantation. Best Pract Res Clin Gastroenterol 2017;31:199-209. [PMID: 28624108 DOI: 10.1016/j.bpg.2017.03.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
27 Brunet M, van Gelder T, Åsberg A, Haufroid V, Hesselink DA, Langman L, Lemaitre F, Marquet P, Seger C, Shipkova M, Vinks A, Wallemacq P, Wieland E, Woillard JB, Barten MJ, Budde K, Colom H, Dieterlen M, Elens L, Johnson-davis KL, Kunicki PK, Macphee I, Masuda S, Mathew BS, Millán O, Mizuno T, Moes DAR, Monchaud C, Noceti O, Pawinski T, Picard N, van Schaik R, Sommerer C, Vethe NT, de Winter B, Christians U, Bergan S. Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report. Therapeutic Drug Monitoring 2019;41:261-307. [DOI: 10.1097/ftd.0000000000000640] [Cited by in Crossref: 131] [Cited by in F6Publishing: 46] [Article Influence: 43.7] [Reference Citation Analysis]
28 Oellerich M, Walson PD, Beck J, Schmitz J, Kollmar O, Schütz E. Graft-Derived Cell-Free DNA as a Marker of Transplant Graft Injury. Therapeutic Drug Monitoring 2016;38:S75-9. [DOI: 10.1097/ftd.0000000000000239] [Cited by in Crossref: 17] [Cited by in F6Publishing: 6] [Article Influence: 2.8] [Reference Citation Analysis]
29 Tanaka M, Iwakiri Y. Lymphatics in the liver. Curr Opin Immunol 2018;53:137-42. [PMID: 29772409 DOI: 10.1016/j.coi.2018.04.028] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 4.5] [Reference Citation Analysis]
30 Rodríguez-perálvarez M, De Luca L, Crespo G, Rubin Á, Marín S, Benlloch S, Colmenero J, Berenguer M, Navasa M, Tsochatzis E, De la Mata M. An objective definition for clinical suspicion of T-cell-mediated rejection after liver transplantation. Clin Transplant 2017;31:e13005. [DOI: 10.1111/ctr.13005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
31 De Luca L, Kalafateli M, Bianchi S, Alasaker N, Buzzetti E, Rodríguez‐perálvarez M, Thorburn D, O'beirne J, Patch D, Leandro G, Westbrook R, Tsochatzis EA. Cardiovascular morbidity and mortality is increased post‐liver transplantation even in recipients with no pre‐existing risk factors. Liver Int 2019;39:1557-65. [DOI: 10.1111/liv.14185] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
32 Gitto S, Villa E. Non-Alcoholic Fatty Liver Disease and Metabolic Syndrome after Liver Transplant. Int J Mol Sci. 2016;17:490. [PMID: 27049380 DOI: 10.3390/ijms17040490] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
33 Giakoustidis AE, Giakoustidis DE. Immunosuppression strategies in liver transplantation patient; patients with hepatocellular carcinoma. Immunotherapy 2017;9:197-206. [PMID: 28128716 DOI: 10.2217/imt-2016-0110] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
34 Del Bello A, Congy-Jolivet N, Danjoux M, Muscari F, Lavayssière L, Esposito L, Hebral AL, Bellière J, Kamar N. High tacrolimus intra-patient variability is associated with graft rejection, and de novo donor-specific antibodies occurrence after liver transplantation. World J Gastroenterol 2018; 24(16): 1795-1802 [PMID: 29713132 DOI: 10.3748/wjg.v24.i16.1795] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 27] [Article Influence: 9.3] [Reference Citation Analysis]
35 Rodríguez-Perálvarez M, Guerrero M, De Luca L, Gros B, Thorburn D, Patch D, Aumente MD, Westbrook R, Fernández R, Amado V, Aguilar P, Montero JL, O'Beirne J, Briceño J, Tsochatzis E, De la Mata M. Area Under Trough Concentrations of Tacrolimus as a Predictor of Progressive Renal Impairment After Liver Transplantation. Transplantation 2019;103:2539-48. [PMID: 31107827 DOI: 10.1097/TP.0000000000002760] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
36 Gotthardt DN, Bruns H, Weiss KH, Schemmer P. Current strategies for immunosuppression following liver transplantation. Langenbecks Arch Surg. 2014;399:981-988. [PMID: 24748543 DOI: 10.1007/s00423-014-1191-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
37 Brunet M, Shipkova M, van Gelder T, Wieland E, Sommerer C, Budde K, Haufroid V, Christians U, López-Hoyos M, Barten MJ. Barcelona Consensus on Biomarker-Based Immunosuppressive Drugs Management in Solid Organ Transplantation. Ther Drug Monit. 2016;38 Suppl 1:S1-S20. [PMID: 26977997 DOI: 10.1097/ftd.0000000000000287] [Cited by in Crossref: 56] [Cited by in F6Publishing: 18] [Article Influence: 9.3] [Reference Citation Analysis]
38 Rodríguez-Perálvarez M, De la Mata M, Burroughs AK. Liver transplantation: immunosuppression and oncology. Curr Opin Organ Transplant. 2014;19:253-260. [PMID: 24685671 DOI: 10.1097/mot.0000000000000069] [Cited by in Crossref: 56] [Cited by in F6Publishing: 25] [Article Influence: 7.0] [Reference Citation Analysis]
39 Hsiao CY, Ho MC, Ho CM, Wu YM, Lee PH, Hu RH. Long-Term Tacrolimus Blood Trough Level and Patient Survival in Adult Liver Transplantation. J Pers Med 2021;11:90. [PMID: 33535628 DOI: 10.3390/jpm11020090] [Reference Citation Analysis]
40 Burra P, Rodriguez-Castro KI. Neoplastic disease after liver transplantation: Focus on de novo neoplasms. World J Gastroenterol 2015; 21(29): 8753-8768 [PMID: 26269665 DOI: 10.3748/wjg.v21.i29.8753] [Cited by in CrossRef: 42] [Cited by in F6Publishing: 35] [Article Influence: 6.0] [Reference Citation Analysis]
41 Khajeh E, Polychronidis G, Ramouz A, Alamdari P, Lemekhova A, Saracevic M, Ali-Hasan-Al-Saegh S, Ghamarnejad O, Majlesara A, Abbasi Dezfouli S, Nickkholgh A, Weiss KH, Rupp C, Mehrabi A, Mieth M. Evaluation of the impact of Tacrolimus-based immunosuppression on Heidelberg liver transplant cohort (HDTACRO): Study protocol for an investigator initiated, non-interventional prospective study. Medicine (Baltimore) 2020;99:e22180. [PMID: 32991411 DOI: 10.1097/MD.0000000000022180] [Reference Citation Analysis]
42 Rodríguez-Perálvarez M, García-Caparrós C, Tsochatzis E, Germani G, Hogan B, Poyato-González A, O’Beirne J, Senzolo M, Guerrero-Misas M, Montero-Álvarez JL. Lack of agreement for defining ‘clinical suspicion of rejection’ in liver transplantation: a model to select candidates for liver biopsy. Transpl Int. 2015;28:455-464. [PMID: 25557691 DOI: 10.1111/tri.12514] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
43 Rodríguez-Perálvarez M, Manousou P, Lerut J, De la Mata M, Burroughs AK. How much immunosuppression is needed after liver transplantation? Clin Transplant 2014;28:6-7. [PMID: 24033553 DOI: 10.1111/ctr.12242] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
44 Lee SK, Lee SW, Jang JW, Bae SH, Choi JY, Yoon SK. Immunological Markers, Prognostic Factors and Challenges Following Curative Treatments for Hepatocellular Carcinoma. Int J Mol Sci 2021;22:10271. [PMID: 34638613 DOI: 10.3390/ijms221910271] [Reference Citation Analysis]
45 Pérez P, Rodríguez-Perálvarez M, Guerrero L, González V, Sánchez R, Centeno M, Poyato A, Briceño J, Sánchez-Frías M, Montero JL, De la Mata M. Incidental hepatocellular carcinoma after liver transplantation: Prevalence, histopathological features and prognostic impact. PLoS One 2017;12:e0175010. [PMID: 28403219 DOI: 10.1371/journal.pone.0175010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
46 Whitehouse GP, Hope A, Sanchez-Fueyo A. Regulatory T-cell therapy in liver transplantation. Transpl Int 2017;30:776-84. [PMID: 28608637 DOI: 10.1111/tri.12998] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 5.3] [Reference Citation Analysis]
47 Wadström J, Ericzon BG, Halloran PF, Bechstein WO, Opelz G, Serón D, Grinyó J, Loupy A, Kuypers D, Mariat C, Clancy M, Jardine AG, Guirado L, Fellström B, O'Grady J, Pirenne J, O'Leary JG, Aluvihare V, Trunečka P, Baccarani U, Neuberger J, Soto-Gutierrez A, Geissler EK, Metzger M, Gray M. Advancing Transplantation: New Questions, New Possibilities in Kidney and Liver Transplantation. Transplantation 2017;101 Suppl 2S:S1-S41. [PMID: 28125449 DOI: 10.1097/TP.0000000000001563] [Cited by in Crossref: 15] [Cited by in F6Publishing: 4] [Article Influence: 3.8] [Reference Citation Analysis]
48 Rodríguez-perálvarez M, Rico-juri JM, Tsochatzis E, Burra P, De la Mata M, Lerut J. Biopsy-proven acute cellular rejection as an efficacy endpoint of randomized trials in liver transplantation: a systematic review and critical appraisal. Transpl Int 2016;29:961-73. [DOI: 10.1111/tri.12737] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.5] [Reference Citation Analysis]
49 Pardo F, Pons JA, Briceño J. V Reunión de Consenso de la Sociedad Española de Trasplante Hepático sobre receptores de riesgo elevado, escenarios actuales de inmunosupresión y manejo del hepatocarcinoma en espera de trasplante. Cirugía Española 2015;93:619-37. [DOI: 10.1016/j.ciresp.2015.04.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
50 Di Maira T, Little EC, Berenguer M. Immunosuppression in liver transplant. Best Practice & Research Clinical Gastroenterology 2020;46-47:101681. [DOI: 10.1016/j.bpg.2020.101681] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
51 Neuberger JM, Bechstein WO, Kuypers DR, Burra P, Citterio F, De Geest S, Duvoux C, Jardine AG, Kamar N, Krämer BK, Metselaar HJ, Nevens F, Pirenne J, Rodríguez-Perálvarez ML, Samuel D, Schneeberger S, Serón D, Trunečka P, Tisone G, van Gelder T. Practical Recommendations for Long-term Management of Modifiable Risks in Kidney and Liver Transplant Recipients: A Guidance Report and Clinical Checklist by the Consensus on Managing Modifiable Risk in Transplantation (COMMIT) Group. Transplantation 2017;101:S1-S56. [PMID: 28328734 DOI: 10.1097/TP.0000000000001651] [Cited by in Crossref: 114] [Cited by in F6Publishing: 43] [Article Influence: 22.8] [Reference Citation Analysis]
52 Gastaca M, Ruiz P, Bustamante J, Martinez-Indart L, Ventoso A, Fernandez JR, Palomares I, Prieto M, Testillano M, Salvador P, Senosiain M, Suárez MJ, Valdivieso A. Early tacrolimus exposure does not impact long-term outcomes after liver transplantation. World J Hepatol 2021; 13(3): 362-374 [PMID: 33815678 DOI: 10.4254/wjh.v13.i3.362] [Reference Citation Analysis]
53 Brister-Smith A, Young JA, Saitman A. A 24-Hour Extended Calibration Strategy for Quantitating Tacrolimus Concentrations by Liquid Chromatography-Tandem Mass Spectrometry. J Appl Lab Med 2021;6:1293-8. [PMID: 34136903 DOI: 10.1093/jalm/jfab048] [Reference Citation Analysis]
54 Zheng J, Wang WL. Risk factors of metabolic syndrome after liver transplantation. Hepatobiliary Pancreat Dis Int. 2015;14:582-587. [PMID: 26663005 DOI: 10.1016/s1499-3872(15)60037-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
55 Oellerich M, Kanzow P, Walson PD. Therapeutic drug monitoring - Key to personalized pharmacotherapy. Clin Biochem 2017;50:375-9. [PMID: 28095311 DOI: 10.1016/j.clinbiochem.2017.01.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
56 Verna EC, Patel YA, Aggarwal A, Desai AP, Frenette C, Pillai AA, Salgia R, Seetharam A, Sharma P, Sherman C, Tsoulfas G, Yao FY. Liver transplantation for hepatocellular carcinoma: Management after the transplant. Am J Transplant 2020;20:333-47. [PMID: 31710773 DOI: 10.1111/ajt.15697] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 7.7] [Reference Citation Analysis]
57 Lerut JP, Gondolesi GE. Immunosuppression in liver and intestinal transplantation. Best Pract Res Clin Gastroenterol 2021;54-55:101767. [PMID: 34874848 DOI: 10.1016/j.bpg.2021.101767] [Reference Citation Analysis]
58 Geng L, Wang LD, Huang JJ, Shen T, Wang ZY, Lin BY, Ye YF, Zheng SS. Lower tacrolimus trough levels in the late period after living donor liver transplantation contribute to improvements in long-term clinical outcomes. Hepatobiliary Pancreat Dis Int. 2018;17:204-209. [PMID: 29807766 DOI: 10.1016/j.hbpd.2018.05.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
59 Rodríguez-Perálvarez M, Pérez-Medrano I, Guerrero-Misas M, González V, Poyato A, Barrera P, Ferrín G, Pozo JC, Sánchez-Frías M, Ciria R. Everolimus is safe within the first month after liver transplantation. Transpl Immunol. 2015;33:146-151. [PMID: 26392195 DOI: 10.1016/j.trim.2015.09.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
60 Trunečka P. Once-daily tacrolimus in liver transplantation: a 'me-too drug', or a therapeutic advantage. Curr Opin Organ Transplant 2017;22:118-22. [PMID: 28079558 DOI: 10.1097/MOT.0000000000000387] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
61 Gérard C, Stocco J, Hulin A, Blanchet B, Verstuyft C, Durand F, Conti F, Duvoux C, Tod M. Determination of the most influential sources of variability in tacrolimus trough blood concentrations in adult liver transplant recipients: a bottom-up approach. AAPS J 2014;16:379-91. [PMID: 24526611 DOI: 10.1208/s12248-014-9577-8] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 3.6] [Reference Citation Analysis]
62 Whitehouse GP, Sanchez-Fueyo A. Immunosuppression withdrawal following liver transplantation. Clin Res Hepatol Gastroenterol. 2014;38:676-680. [PMID: 25281267 DOI: 10.1016/j.clinre.2014.06.011] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]